Abstract
Significant advances in DNA sequencing now permit the sequencing of an individual's whole genome for ∼$1,000. This will soon result in a paradigm shift in how we approach the diagnosis and treatment of rare and common diseases.1 The question we should carefully consider is whether whole genome sequencing (WGS) is ready for routine use in clinical practice. While one WGS sample can generate gigabytes of data, whether these data can generate meaningful information is significantly more complex. Analysis of the raw data requires specialized bioinformatics expertise and complicated software. Poor initial analysis of the raw …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
